Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated <em>NPM1</em> and rearranged <em>CBF</em>

Publication date: Available online 30 September 2023Source: Leukemia ResearchAuthor(s): Carlos Jiménez-Vicente, Alexandra Martínez-Roca, Helena Pomares, Sandra Castaño-Diez, Francesca Guijarro, Mònica López-Guerra, Alex Bataller, Daniel Esteban, Albert…